Susceptibility to human cancer: From the perspective of a pathologist

Sugimura, Haruhiko

doi:10.1111/pin.12418

Cited by 9 publications

(8 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the present time, which has seen rapid strides in the development of omics analysis technologies, such as genome analysis, it is expected that data‐driven studies based on analysis of clinical samples will help clarify the molecular mechanisms responsible for the occurrence, progression and treatment responsiveness of diseases, thereby leading to the development of new biomarkers for diagnosis and identification of drug discovery targets . In particular, analysis of pathological tissue samples collected from the exact site of a disease, such as cancer, will be indispensable for the realization of genomic medicine …”

mentioning

confidence: 99%

“…3 In particular, analysis of pathological tissue samples collected from the exact site of a disease, such as cancer, will be indispensable for the realization of genomic medicine. [4][5][6][7][8][9][10][11][12] Besides detailed and accurate clinicopathological information about pathological tissue samples, the quality of the tissue samples itself holds the key to the success of such data-driven studies. 13,14 Appropriate collection and storage of pathological tissue samples enables reliable and high-quality analyses that can contribute to prevention and treatment of diseases.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses

Kanai

Nishihara

Miyagi

et al. 2018

Pathology International

View full text Add to dashboard Cite

Genome research using appropriately collected pathological tissue samples is expected to yield breakthroughs in the development of biomarkers and identification of therapeutic targets for diseases such as cancers. In this connection, the Japanese Society of Pathology (JSP) has developed “The JSP Guidelines on the Handling of Pathological Tissue Samples for Genomic Research” based on an abundance of data from empirical analyses of tissue samples collected and stored under various conditions. Tissue samples should be collected from appropriate sites within surgically resected specimens, without disturbing the features on which pathological diagnosis is based, while avoiding bleeding or necrotic foci. They should be collected as soon as possible after resection: at the latest within about 3 h of storage at 4°C. Preferably, snap‐frozen samples should be stored in liquid nitrogen (about −180°C) until use. When intending to use genomic DNA extracted from formalin‐fixed paraffin‐embedded tissue, 10% neutral buffered formalin should be used. Insufficient fixation and overfixation must both be avoided. We hope that pathologists, clinicians, clinical laboratory technicians and biobank operators will come to master the handling of pathological tissue samples based on the standard operating procedures in these Guidelines to yield results that will assist in the realization of genomic medicine.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses

Kanai

Nishihara

Miyagi

et al. 2018

Pathology International

View full text Add to dashboard Cite

show abstract

“…Thus, findings from MPE research can provide biological evidence to enhance our understanding of etiologies and pathogenesis of diseases, strengthening evidence for causal relationships [1, 2, 7, 8]. The concept of this unified field of MPE has gained considerable popularity in the literature [9–30]. …”

Section: Introduction To Molecular Pathological Epidemiology (Mpe)mentioning

confidence: 99%

Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis

et al. 2016

View full text Add to dashboard Cite

Molecular pathological epidemiology (MPE) is an integrative field that utilizes molecular pathology to incorporate interpersonal heterogeneity of a disease process into epidemiology. In each individual, the development and progression of a disease are determined by a unique combination of exogenous and endogenous factors, resulting in different molecular and pathological subtypes of the disease. Based on “the unique disease principle,” the primary aim of MPE is to uncover an interactive relationship between a specific environmental exposure and disease subtypes in determining disease incidence and mortality. This MPE approach can provide etiologic and pathogenic insights, potentially contributing to precision medicine for personalized prevention and treatment. Although breast, prostate, lung, and colorectal cancers have been among the most commonly studied diseases, the MPE approach can be used to study any disease. In addition to molecular features, host immune status and microbiome profile likely affect a disease process, and thus serve as informative biomarkers. As such, further integration of several disciplines into MPE has been achieved (e.g., pharmaco-MPE, immuno-MPE, and microbial MPE), to provide novel insights into underlying etiologic mechanisms. With the advent of high-throughput sequencing technologies, available genomic and epigenomic data have expanded dramatically. The MPE approach can also provide a specific risk estimate for each disease subgroup, thereby enhancing the impact of genome-wide association studies on public health. In this article, we present recent progress of MPE, and discuss the importance of accounting for the disease heterogeneity in the era of big-data health science and precision medicine.

show abstract

“…In the era that we have entered after the human genome sequencing project, the expectation and enthusiasm for individually tailored medicine (so‐called precision medicine) have been intensifying in practical settings, including in the field of pathological diagnosis. Monthly updates on the possibilities of wiser usage of molecular technologies are being published in every area of medicine . The laboratory of diagnostic pathology, the most of the readers of Pathology International reside in is no exception.…”

mentioning

confidence: 99%

Editorial Comment on Validation of the digital PCR system for use in tyrosine kinase inhibitor‐resistant EGFR‐mutant non‐small‐cell lung cancer

Sugimura

Kahyo

2018

Pathology International

Self Cite

View full text Add to dashboard Cite

Susceptibility to human cancer: From the perspective of a pathologist

Cited by 9 publications

References 90 publications

The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses

The Japanese Society of Pathology Guidelines on the handling of pathological tissue samples for genomic research: Standard operating procedures based on empirical analyses

Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis

Editorial Comment on Validation of the digital PCR system for use in tyrosine kinase inhibitor‐resistant EGFR‐mutant non‐small‐cell lung cancer

Contact Info

Product

Resources

About